Ipsen appoints Michelle C. Werner as EVP, President of North America

About this update from Ipsen Sa

[{"type":"image","alt":"Ipsen Pharma","displaySize":"","headline":null,"caption":"Ipsen Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/e6eb628cc0e353381e6b738c556a0e31"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/89RavcsKEHEdDt270X336Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e6eb628cc0e353381e6b738c556a0e31","width":300,"height":157}},"lazy":false},{"type":"text","content":"Michelle C. Werner","length":18,"tagName":"p"},{"type":"image","alt":"Photo of Michelle C. Werner, EVP, President of North America","displaySize":"","headline":null,"caption":"Photo of Michelle C. Werner, EVP, President of North America","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":5178,"height":7764,"url":"https://media.zenfs.com/en/globenewswire.com/9c984f3974c5150132295e391d30ab01"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tuxkajtpc9gJiQLwfBqC7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE0Mzk7Y2Y9d2VicA--/https://media.zenfs.com/en/globenewswire.com/9c984f3974c5150132295e391d30ab01","width":960,"height":1439},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/rGRz.Wtsa8Nv5MTJ6FVojg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zNTk4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/9c984f3974c5150132295e391d30ab01","width":1200,"height":1799}}},{"type":"text","content":"PARIS, FRANCE, 12 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Michelle C. Werner as Executive Vice President (EVP), President of North America, effective 23 March 2026. Michelle will serve on the Executive Leadership Team (ELT) and will report directly to Ipsen’s Chief Executive Officer (CEO), David Loew.","length":344,"tagName":"p"},{"type":"text","content":"“I am very pleased to welcome Michelle to Ipsen and to the Executive Leadership Team. She brings a wealth of experience in leading teams both in the U.S. and around the world and has a deep understanding of the United States and all the great opportunities that this market offers for Ipsen at a moment when we are accelerating the growth of our portfolio in rare diseases, oncology and neurosciences. These are therapeutic areas where Michelle has excelled over her extensive career” declared David Loew, C...

More updates from Ipsen Sa